Date: 2014-03-03
Type of information: Milestone
Compound: molecules that aim to correct the mitochondrial dysfunction associated with certain pathologies including metabolic diseases
Company: Genfit (France) Sanofi (France)
Therapeutic area: Metabolic diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: * On March 17, 2011, Genfit has signed a new contract with Sanofi for the research and development of new drugs for the treatment of metabolic disorders. Through this agreement, Sanofi obtains the exclusive worldwide rights to develop and commercialize molecules resulting from the research collaboration. In exchange, Genfit will receive annual payments and could receive additional milestone payments according to the progress of the development, registration, and commercialization of the resulting products. Within this research program, Genfit will collaborate with Sanofi to identify molecules that aim to correct the mitochondrial dysfunction associated with certain pathologies including metabolic diseases. Indeed, based on clinical observations, the cellular mechanisms that regulate energy production under normal conditions, and their capacity to adapt to stress, may have therapeutic potential in such disorders.
Financial terms: According to the terms of the alliance, Genfit will receive annual payments to fund research within the collaboration, in addition to milestone payments according to the progress of preclinical and clinical development, and the subsequent registration and commercialization of resulting products. The total of these milestone payments could reach $54.5 million (€ 39 million). Genfit will also receive royalties from future sales of products developed by Sanofi that result from the collaboration.
Latest news: * On March 3, 2014, Genfit has announced the demonstration of the beneficial effects of several molecules in various in vivo models related to the diseases targeted in its research collaboration with Sanofi. The achievement of this new key milestone, after those achieved in April 2012 and January 2013, comes within the co-research contract signed between the two Companies in March 2011. In this partnership, Genfit collaborates with Sanofi to develop new medicines to correct the mitochondrial dysfunction associated with certain metabolic disorders, in particular Type 2 diabetes. In accordance with the terms of the contract, whereby Sanofi obtained the exclusive worldwide rights to develop and commercialize the molecules arising from the research collaboration, Genfit has received the third of the milestone payments included in the collaboration and licensing agreement. Depending on the preclinical and clinical development, and the subsequent registration and commercialization of resulting products, the total of Genfit’s milestone payments included in the agreement could reach $54 million (€39 million), in addition to royalties from future sales of products developed by Sanofi and resulting from the
collaboration.
